Discovery of a potent and selective ATAD2 inhibitor with antiproliferative activity in breast cancer models

被引：0
|
作者：
Kulkarni, Meghana M. [1 ]
Winter, Jon [2 ]
Whalley, David [3 ]
Dale, Ian [2 ]
Denz, Christopher [1 ]
Guan, Nin [1 ]
Bhavsar, Deepa [1 ]
Zhang, Andrew [1 ]
Rasmusson, Timothy [1 ]
Fretland, Adrian [1 ]
Guichard, Sylvie M. [1 ]
机构：
[1] AstraZeneca, Waltham, MA USA
[2] AstraZeneca, Cambridge, England
[3] AstraZeneca, Waltham, England
来源：
MOLECULAR CANCER THERAPEUTICS | 2018年 / 17卷 / 01期
关键词：
D O I：
10.1158/1535-7163.TARG-17-A170
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
A170
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Oncogene ATAD2 promotes cell proliferation, invasion and migration in cervical cancer
    Zheng, Le
    Li, Tianren
    Zhang, Yi
    Guo, Yi
    Yao, Jihang
    Dou, Lei
    Guo, Kejun
    ONCOLOGY REPORTS, 2015, 33 (05) : 2337 - 2344
  • [22] ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE
    Guruvaiah, Praveen
    Chava, Suresh
    Sun, Chiao-Wang
    Singh, Nirupama
    Penn, Courtney A.
    Gupta, Romi
    CELL DEATH & DISEASE, 2023, 14 (07)
  • [23] ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker
    Zhang, M-J.
    Zhang, C. -Z.
    Du, W. -J.
    Yang, X. -Z.
    Chen, Z. -P.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2016, 18 (08): : 776 - 781
  • [24] ATAD2 is a driver and a therapeutic target in ovarian cancer that functions by upregulating CENPE
    Praveen Guruvaiah
    Suresh Chava
    Chiao-Wang Sun
    Nirupama Singh
    Courtney A. Penn
    Romi Gupta
    Cell Death & Disease, 14
  • [25] Discovery of a potent and selective Aurora kinase inhibitor
    Oslob, Johan D.
    Romanowski, Michael J.
    Allen, Darin A.
    Baskaran, Subramanian
    Bui, Minna
    Elling, Robert A.
    Flanagan, William M.
    Fung, Amy D.
    Hanan, Emily J.
    Harris, Shannon
    Heumann, Stacey A.
    Hoch, Ute
    Jacobs, Jeffrey W.
    Lam, Joni
    Lawrence, Chris E.
    McDowell, Robert S.
    Nannini, Michelle A.
    Shen, Wang
    Silverman, Jeffrey A.
    Sopko, Michelle M.
    Tangonan, Bradley T.
    Teague, Juli
    Yoburn, Josh C.
    Yu, Chul H.
    Zhong, Min
    Zimmerman, Kristin M.
    O'Brien, Tom
    Lew, Willard
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2008, 18 (17) : 4880 - 4884
  • [26] BET inhibitors induce apoptosis through ATAD2 suppression in AR positive triple negative breast cancer cells
    Yang, H.
    Shim, S. H.
    Lee, K. S.
    Park, I. H.
    ANNALS OF ONCOLOGY, 2017, 28 : 4 - 4
  • [27] Reading the message: A structural and functional comparison of the ATAD2/B bromodomain binding activity
    Glass, Karen
    ACTA CRYSTALLOGRAPHICA A-FOUNDATION AND ADVANCES, 2022, 78 : A100 - A100
  • [28] Discovery of GH1581, a potent and selective WRN inhibitor as a cancer therapy
    Li, Jiapeng
    Zhang, Guiping
    Li, Jie Jack
    CANCER RESEARCH, 2024, 84 (06)
  • [29] A novel histone deacetylase inhibitor with potent antiproliferative activity in ovarian cancer cells.
    Mand, Michael
    Edwards, Ceazon
    Tumati, Vasu
    Kulp, Samuel K.
    Chen, Ching-Shih
    Nephew, Kenneth P.
    Balch, Curtis
    CANCER RESEARCH, 2006, 66 (08)
  • [30] ARIMIDEX: A potent and selective aromatase inhibitor for the treatment of advanced breast cancer
    Buzdar, AU
    Jonat, W
    Howell, A
    Plourde, PV
    JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY, 1997, 61 (3-6): : 145 - 149
12345